Larimar Therapeutics
Most recent annual filing: 2026-03-15
- nomlabofusp Ph3 start3Q 2026nomlabofusp Ph3 start, 3Q 2026, routine
- fill-and-finish manufacturing update2H 2026/1H 2027fill-and-finish manufacturing update, 2H 2026/1H 2027, routine
- corporate financing2H 2026/1H 2027corporate financing, 2H 2026/1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
CPP
Cell penetrating peptide (CPP) technology platform enabling therapeutic molecules to cross cell membranes and reach intracellular targets, including mitochondria; focused on rare and orphan diseases characterized by deficiencies in or alterations of intracellular content or activity
intracellular delivery platform
Intracellular delivery platform used to design fusion proteins targeting rare diseases characterized by deficiencies in intracellular bioactive compounds
Biotech Distilled coverage (5)
- 2026-08-05 UPDATE: Larimar (LRMR) - The Form 483 Buried in the 10-Q 🔒 Paid
- 2026-06-30 UPDATE: Larimar (LRMR) - The BLA Clock Starts 🔒 Paid
- 2026-03-21 UPDATE: Larimar (LRMR) - The $63 Million Tell 🔒 Paid
- 2026-02-28 UPDATE: Larimar (LRMR) - The FDA Blinks, Larimar Squeezes, and the Dilution Gap Closes 🔒 Paid
- 2026-01-11 Larimar Therapeutics (LRMR): Scientific Deep Dive for Nomlabofusp and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.